151 related articles for article (PubMed ID: 12116552)
1. [The treatment options broaden. New chances for libido].
Einecke U
MMW Fortschr Med; 2002 May; 144(19):4-6. PubMed ID: 12116552
[No Abstract] [Full Text] [Related]
2. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Roumeguère T; Sternon J; Schulman CC
Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
[TBL] [Abstract][Full Text] [Related]
3. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
4. [Therapy of erectile dysfunction. Hard facts support sildenafil].
MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
[No Abstract] [Full Text] [Related]
5. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
[No Abstract] [Full Text] [Related]
6. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
MMW Fortschr Med; 2004 Apr; 146(16):62. PubMed ID: 15222506
[No Abstract] [Full Text] [Related]
7. [7 years PDE-5 inhibitor for therapy of erection disorders].
Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
[No Abstract] [Full Text] [Related]
8. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
9. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
Carson CC
J Urol; 2002 Jul; 168(1):205. PubMed ID: 12073960
[No Abstract] [Full Text] [Related]
10. Chapter 1: The management of erectile dysfunction: an AUA update.
Montague DK; Jarow JP; Broderick GA; Dmochowski RR; Heaton JP; Lue TF; Milbank AJ; Nehra A; Sharlip ID;
J Urol; 2005 Jul; 174(1):230-9. PubMed ID: 15947645
[No Abstract] [Full Text] [Related]
11. Oral drug treatment of erectile dysfunction.
Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
[No Abstract] [Full Text] [Related]
12. [Some aspects of erectile dysfunction pathogenesis and treatment in patients with obesity].
Ametov AS; Teodorovich OV; Kondrat'eva LV; Popova AIu
Ter Arkh; 2006; 78(2):92-4. PubMed ID: 16613108
[No Abstract] [Full Text] [Related]
13. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
Steers WD
J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
[No Abstract] [Full Text] [Related]
14. Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
Kim NN
Int J Impot Res; 2003 Oct; 15 Suppl 5():S13-9. PubMed ID: 14551572
[TBL] [Abstract][Full Text] [Related]
15. PDE5 inhibitors: looking beyond ED.
Jackson G
Int J Clin Pract; 2003 Apr; 57(3):159-60. PubMed ID: 12723713
[No Abstract] [Full Text] [Related]
16. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Küthe A; Montorsi F; Andersson KE; Stief CG
Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide regulation of penile erection: biology and therapeutic implications.
Burnett AL
J Androl; 2002; 23(5):S20-6. PubMed ID: 12236169
[No Abstract] [Full Text] [Related]
18. Erectile dysfunction.
Shabsigh R; Anastasiadis AG
Annu Rev Med; 2003; 54():153-68. PubMed ID: 12525671
[TBL] [Abstract][Full Text] [Related]
19. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
Lee AG; Newman NJ
Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
[No Abstract] [Full Text] [Related]
20. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
